Literature DB >> 16553928

The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania.

J-A Mulligan1, R Mandike, N Palmer, H Williams, S Abdulla, P Bloland, A Mills.   

Abstract

OBJECTIVE: To document the cost incurred by the Tanzanian government by changing the policy on first-line treatment of malaria, from chloroquine to sulfadoxine-pyrimethamine.
METHODS: Costs were analysed from the perspective of the Ministry of Health and included all sources of funding. Costs external to the public health sector (e.g. private and community costs) were not included. The base case analysis adopted an incremental rather than a full cost approach, assuming that an organizational infrastructure was already in place. However, specific attention was paid to the burden placed on National Malaria Control Program staff. We also costed activities planned but not implemented to estimate the total expense for an 'ideal' process.
RESULTS: Total costs were Tsh 795 million (USD 813,743), with the largest proportion accounted for by training. Costs of the policy change process were equivalent to about 4% of annual government and donor expenditure on malaria and to about 1% of overall public expenditure on health. A number of planned activities were not implemented; including these would bring the total cost to Ts 880 million (USD 896,130).
CONCLUSION: On top of extra costs for the drugs themselves, a change in treatment policy requires time, resources and substantial management capacity at national and local level. A better understanding of these issues and the costs involved benefits countries planning and implementing policy change.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553928     DOI: 10.1111/j.1365-3156.2006.01590.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  30 in total

1.  Malaria parasitemia and CD4 T cell count, viral load, and adverse HIV outcomes among HIV-infected pregnant women in Tanzania.

Authors:  Molly F Franke; Donna Spiegelman; Amara Ezeamama; Said Aboud; Gernard I Msamanga; Saurabh Mehta; Wafaie W Fawzi
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

Review 2.  Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.

Authors:  Ambrose O Talisuna; Corine Karema; Bernhards Ogutu; Elizabeth Juma; John Logedi; Andrew Nyandigisi; Modest Mulenga; Wilfred F Mbacham; Cally Roper; Philippe J Guerin; Umberto D'Alessandro; Robert W Snow
Journal:  Lancet Infect Dis       Date:  2012-11       Impact factor: 25.071

3.  Availability of antimalarial drugs and evaluation of the attitude and practices for the treatment of uncomplicated malaria in bangui, central african republic.

Authors:  Alexandre Manirakiza; Siméon Pierre Njuimo; Alain Le Faou; Denis Malvy; Pascal Millet
Journal:  J Trop Med       Date:  2010-03-14

4.  Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness.

Authors:  James Buchanan; Borislava Mihaylova; Alastair Gray; Nicholas White
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

5.  Taking stock: provider prescribing practices in the presence and absence of ACT stock.

Authors:  Bernadette Hensen; Lucy Smith Paintain; Rima Shretta; Jane Bruce; Caroline Jones; Jayne Webster
Journal:  Malar J       Date:  2011-08-03       Impact factor: 2.979

6.  Acquired resistance of malarial parasites against artemisinin-based drugs: social and economic impacts.

Authors:  Johanna M Porter-Kelley; Joann Cofie; Sophonie Jean; Mark E Brooks; Mia Lassiter; Dc Ghislaine Mayer
Journal:  Infect Drug Resist       Date:  2010-08-09       Impact factor: 4.003

7.  Malaria treatment policy change and implementation: the case of Uganda.

Authors:  Miriam Nanyunja; Juliet Nabyonga Orem; Frederick Kato; Mugagga Kaggwa; Charles Katureebe; Joaquim Saweka
Journal:  Malar Res Treat       Date:  2011-09-19

8.  Country planning for health interventions under development: lessons from the malaria vaccine decision-making framework and implications for other new interventions.

Authors:  Alan Brooks; Antoinette Ba-Nguz
Journal:  Health Policy Plan       Date:  2012-05       Impact factor: 3.344

9.  Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.

Authors:  Angela Devine; Katherine E Battle; Niamh Meagher; Rosalind E Howes; Saber Dini; Peter W Gething; Julie A Simpson; Ric N Price; Yoel Lubell
Journal:  PLoS Med       Date:  2021-06-01       Impact factor: 11.069

10.  Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine.

Authors:  Beatrice Wasunna; Dejan Zurovac; Catherine A Goodman; Robert W Snow
Journal:  Malar J       Date:  2008-02-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.